This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter

Cormorant Asset Management sold 50,000 Praxis Precision Medicines (PRAX) shares in Q4 2025 (estimated $9.31M) while the quarter-end value of the PRAX stake rose by $227.0M to 950,000 shares valued at $280.0M (12.9% of AUM). PRAX was trading at $305 as of Monday, up ~700% over the past year. Praxis finished 2025 with ~ $926M cash and investments and completed a $621M offering in January, which management says funds operations into 2028; the firm has advanced NDAs for late-stage candidates, supporting a potential transition to commercialization.

Analysis

Cormorant’s modest trim in a very large, concentrated neuroscience stake reads like classic position management rather than a change in thesis: they reduced idiosyncratic tail risk while keeping significant exposure to late-stage readouts and potential commercialization optionality. With the balance sheet bolstered earlier this year, the real near-term value driver is binary clinical/regulatory outcomes and the subsequent speed of payer adoption — outcomes that can compress or expand implied multiples by >50% inside 6–12 months.

Liquidity and market-structure dynamics matter more than they do for broad-cap names: sustained retail/momentum flows into a limited-float biotech can create asymmetric intraday moves, making passive arbitrage (eg, index or ETF hedges) imperfect. Large holder activity creates transient supply that can cap rallies and provide tactical entry windows, but it also increases the chance of cliff-like price moves around announcements or index rebalance windows.

Second-order commercial risks are under-discussed: transitioning from development to commercialization requires specialty sales, REMS programs, and favorable formulary placement — each a multi-quarter gating item that can delay revenue recognition and re-rate multiples even post-approval. Conversely, a clean regulatory path opens optionality for partnerships or acquisition discussions, which typically surface within 6–18 months and can materially reprice the equity beyond simple product sales scenarios.

Net: the name is a binary, high-conviction asymmetric payoff where disciplined position sizing and explicit event hedges dominate stock selection. Timing should be event-aware (PDUFA/advisory windows) and execution mindful of limited liquidity and potential for large, short-term spread widening.

Key Decisions for Investors

• Event-driven long with protection: Initiate a modest 1–2% AUM long position via stock or 12–18 month LEAP calls to capture upside to regulatory/commercial outcomes, and finance ~30–40% of cost by selling 2–3 month OTM calls at ~15–20% OTM. R/R: asymmetric — 50–150% upside on positive readouts within 12 months vs 35–60% downside on negative outcomes; hedge reduces net theta drag.
• Hedge binary risk with index-short: Pair the long position with a short biotech basket (eg, IBB short or a basket of small-cap neuro development peers) sized to neutralize market beta by notional. Timeframe: maintain through next 6–12 months of clinical/regulatory catalysts. This isolates program-specific upside while capping sector drawdown.
• Tactical volatility play: Sell a calendar spread (short near-term straddles / long further-dated) around expected announcements to capture elevated IV ahead of events, limiting exposure to directional moves. Risk: large move on an unexpected result; recommended size <0.5% AUM.
• Contrarian re-rate trade: If the name gaps down >20% on event noise (not safety failure), accumulate additional exposure to 2–3% AUM, layering in protection via puts expiring 9–12 months out to cap downside while keeping optional upside for partnership/M&A catalysts.
• Liquidity-aware execution: Use VWAP/TWAP algorithms and stagger entries over 2–10 trading days for any position >0.25% AUM to avoid market impact; set alerts for index reconstitution dates and large-block prints as potential short-term volatility triggers.